Marker Therapeutics (MRKR) Revenue & Revenue Breakdown
Marker Therapeutics Revenue Highlights
Latest Revenue (Y)
$3.31M
Latest Revenue (Q)
$1.17M
Main Segment (Y)
Related Party Service
Marker Therapeutics Revenue by Period
Marker Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $3.31M | -63.23% |
| 2022-12-31 | $9.00M | 625.17% |
| 2021-12-31 | $1.24M | 166.01% |
| 2020-12-31 | $466.79K | 118.95% |
| 2019-12-31 | $213.19K | 3.50% |
| 2018-12-31 | $205.99K | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2011-12-31 | - | 100.00% |
| 2010-12-31 | - | 100.00% |
| 2009-12-31 | - | 100.00% |
| 2008-12-31 | - | 100.00% |
| 2007-12-31 | - | 100.00% |
| 2006-12-31 | - | 100.00% |
| 2005-12-31 | - | 100.00% |
| 2004-12-31 | - | 100.00% |
| 2003-12-31 | - | 100.00% |
| 2002-12-31 | - | 100.00% |
| 2001-12-31 | - | -100.00% |
| 2000-12-31 | $25.05K | -79.25% |
| 1999-12-31 | $120.72K | - |
Marker Therapeutics generated $3.31M in revenue during NA 2023, up -63.23% compared to the previous quarter, and up 1607.39% compared to the same period a year ago.
Marker Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $1.17M | -6.01% |
| 2024-03-31 | $1.24M | 17.75% |
| 2023-12-31 | $1.06M | 310.13% |
| 2023-09-30 | $257.61K | -66.22% |
| 2023-06-30 | $762.66K | -78.21% |
| 2023-03-31 | $3.50M | -42.19% |
| 2022-12-31 | $6.05M | 105.24% |
| 2022-09-30 | $2.95M | 272.95% |
| 2022-06-30 | $791.00K | -17.95% |
| 2022-03-31 | $964.00K | -22.37% |
| 2021-12-31 | $1.24M | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | -100.00% |
| 2020-12-31 | $215.00 | 100.00% |
| 2020-09-30 | - | -100.00% |
| 2020-06-30 | $466.79K | 100.00% |
| 2020-03-31 | - | -100.00% |
| 2019-12-31 | $213.19K | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | -100.00% |
| 2018-12-31 | $6.00 | 100.00% |
| 2018-09-30 | - | -100.00% |
| 2018-06-30 | $205.99K | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | -100.00% |
| 2017-09-30 | $183.06K | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-10-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2012-09-30 | - | 100.00% |
| 2012-06-30 | - | 100.00% |
| 2012-03-31 | - | 100.00% |
| 2011-12-31 | - | 100.00% |
| 2011-09-30 | - | 100.00% |
| 2011-06-30 | - | 100.00% |
| 2011-03-31 | - | 100.00% |
| 2010-12-31 | - | 100.00% |
| 2010-09-30 | - | 100.00% |
| 2010-06-30 | - | 100.00% |
| 2010-03-31 | - | 100.00% |
| 2009-12-31 | - | 100.00% |
| 2009-09-30 | - | 100.00% |
| 2009-06-30 | - | 100.00% |
| 2009-03-31 | - | 100.00% |
| 2008-12-31 | - | 100.00% |
| 2008-09-30 | - | 100.00% |
| 2008-06-30 | - | 100.00% |
| 2008-03-31 | - | 100.00% |
| 2007-12-31 | - | - |
Marker Therapeutics generated $1.17M in revenue during Q2 2024, up -6.01% compared to the previous quarter, and up 33.41% compared to the same period a year ago.
Marker Therapeutics Revenue Breakdown
Marker Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Related Party Service | $3.50M | - | - | - | - |
| Service | $816.64K | $5.50M | - | - | - |
| Grant | - | $3.51M | $466.79K | $213.19K | - |
| Grant income | - | - | $1.24M | - | - |
Marker Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Related Party Service (81.08%), and Service (18.92%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Dec 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 19 |
|---|---|---|---|---|---|---|---|---|---|
| Grant | $1.17M | $1.24M | $1.23M | $759.14K | $999.57K | $213.19K | - | - | - |
| Service | - | - | - | $3.50M | $2.55M | - | - | - | - |
| Grant income | - | - | - | - | - | - | $790.51K | $964.32K | - |
Marker Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Grant (100.00%).
Marker Therapeutics Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 19 |
|---|---|---|---|---|---|---|
| Service | $3.50M | $2.55M | - | - | - | - |
| Grant | $1.23M | $759.14K | $999.57K | $213.19K | - | - |
| Grant income | - | - | - | $790.51K | $964.32K | - |
Marker Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 23: Service (73.93%), and Grant (26.07%).
Marker Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AGEN | Agenus | $156.31M | $23.51M |
| ALEC | Alector | $97.06M | $15.89M |
| AADI | Aadi Bioscience | $24.35M | $6.18M |
| IKNA | Ikena Oncology | $9.16M | - |
| MRKR | Marker Therapeutics | $3.31M | $1.17M |
| LUMO | Lumos Pharma | $2.05M | $488.00K |
| CBIO | Gyre Therapeutics | $794.00K | - |
| KROS | Keros Therapeutics | $151.00K | $83.00K |
| ANEB | Anebulo Pharmaceuticals | - | - |
| XCUR | Exicure | - | - |
| BNOX | Bionomics | - | $98.94K |
| AVTE | Aerovate Therapeutics | - | - |
| RNXT | RenovoRx | - | - |
| TPST | Tempest Therapeutics | - | - |
| ACRV | Acrivon Therapeutics | - | - |
| PMVP | PMV Pharmaceuticals | - | - |
| PTIX | Protagenic Therapeutics | - | - |
| EWTX | Edgewise Therapeutics | - | - |
MRKR Revenue FAQ
What is Marker Therapeutics’s yearly revenue?
Marker Therapeutics's yearly revenue for 2023 was $3.31M, representing a decrease of -63.23% compared to 2022. The company's yearly revenue for 2022 was $9M, representing an increase of 625.17% compared to 2021. MRKR's yearly revenue for 2021 was $1.24M, representing an increase of 166.01% compared to 2020.
What is Marker Therapeutics’s quarterly revenue?
Marker Therapeutics's quarterly revenue for Q2 2024 was $1.17M, a -6.01% decrease from the previous quarter (Q1 2024), and a 53.31% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $1.24M, a 17.75% increase from the previous quarter (Q4 2023), and a -64.46% decrease year-over-year (Q1 2023). MRKR's quarterly revenue for Q4 2023 was $1.06M, a 310.13% increase from the previous quarter (Q3 2023), and a -82.55% decrease year-over-year (Q4 2022).
What is Marker Therapeutics’s revenue growth rate?
Marker Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 166.66%, and for the last 5 years (2019-2023) was 1453.11%.
What are Marker Therapeutics’s revenue streams?
Marker Therapeutics's revenue streams in c 23 are Related Party Service, and Service. Related Party Service generated $3.5M in revenue, accounting 81.08% of the company's total revenue Service generated $816.64K in revenue, accounting 18.92% of the company's total revenue, down -85.15% year-over-year.
What is Marker Therapeutics’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Marker Therapeutics was Related Party Service. This segment made a revenue of $3.5M, representing 81.08% of the company's total revenue.